drugset
drugset / Trial / NCT04509466

Clinical Study of Liposomal Mitoxantrone Hydrochloride Injection Combined With Pegaspargase in the Treatment of NKTCL

NCT04509466 ↗

Phase 1/2 Terminated 41 enrolled CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
NaSingle-groupOpen-labelTreatment

Summary

This is a multicentre, open-label, single-arm, phase I/II clinical study to evaluate the safety, efficacy and pharmacokinetics of liposomal mitoxantrone hydrochloride in combination with pegaspargase in patients with extranodal natural killer/T-cell lymphoma, nasal type (NKTCL).

Timeline

Start
2020-09-15
Primary completion
2022-01-30
Completion
2022-01-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Mitoxantrone Small molecule 12 mg/m2 Intravenous
Subject Mitoxantrone Small molecule 16 mg/m2 Intravenous
Subject Mitoxantrone Small molecule 20 mg/m2 Intravenous
Subject Mitoxantrone Small molecule 24 mg/m2 Intravenous
Subject Pegaspargase Protein / enzyme biologic 2000 unknown Intramuscular

Indications

extranodal nasal NK/T cell lymphoma